

Fang-Hui Zhao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2056926/publications.pdf>

Version: 2024-02-01

122
papers

4,314
citations

147566

31
h-index

133063

59
g-index

139
all docs

139
docs citations

139
times ranked

3353
citing authors

#	ARTICLE	IF	CITATIONS
1	Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. <i>Lancet Oncology, The</i> , 2014, 15, 172-183.	5.1	508
2	A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. <i>Lancet Oncology, The</i> , 2008, 9, 929-936.	5.1	416
3	Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: A pooled analysis of 17 population-based studies. <i>International Journal of Cancer</i> , 2012, 131, 2929-2938.	2.3	155
4	Pooled Analysis of a Self-Sampling HPV DNA Test as a Cervical Cancer Primary Screening Method. <i>Journal of the National Cancer Institute</i> , 2012, 104, 178-188.	3.0	139
5	Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. <i>Lancet Oncology, The</i> , 2010, 11, 1160-1171.	5.1	129
6	The IARC Perspective on Cervical Cancer Screening. <i>New England Journal of Medicine</i> , 2021, 385, 1908-1918.	13.9	125
7	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1083-1095.	2.8	116
8	Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 145-153.	3.0	99
9	A multi-center survey of age of sexual debut and sexual behavior in Chinese women: Suggestions for optimal age of human papillomavirus vaccination in China. <i>Cancer Epidemiology</i> , 2012, 36, 384-390.	0.8	95
10	Cervical cancer prevention in China: a key to cancer control. <i>Lancet, The</i> , 2019, 393, 969-970.	6.3	93
11	An Evaluation of Novel, Lower-Cost Molecular Screening Tests for Human Papillomavirus in Rural China. <i>Cancer Prevention Research</i> , 2013, 6, 938-948.	0.7	88
12	Lower cost strategies for triage of human papillomavirus DNA-positive women. <i>International Journal of Cancer</i> , 2014, 134, 2891-2901.	2.3	80
13	Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies. <i>Vaccine</i> , 2011, 29, 2487-2494.	1.7	69
14	Effect of an educational intervention on HPV knowledge and vaccine attitudes among urban employed women and female undergraduate students in China: a cross-sectional study. <i>BMC Public Health</i> , 2013, 13, 916.	1.2	66
15	No association between HPV infection and the neoplastic progression of esophageal squamous cell carcinoma: Result from a cross-sectional study in a high-risk region of China. <i>International Journal of Cancer</i> , 2006, 119, 1354-1359.	2.3	63
16	Perceptions and acceptability of HPV vaccination among parents of young adolescents: A multicenter national survey in China. <i>Vaccine</i> , 2013, 31, 3244-3249.	1.7	61
17	p16 ^{INK4A} immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: A prospective study in China. <i>International Journal of Cancer</i> , 2014, 134, 1715-1724.	2.3	57
18	A Multi-center Survey of HPV Knowledge and Attitudes Toward HPV Vaccination among Women, Government Officials, and Medical Personnel in China. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 2369-2378.	0.5	52

#	ARTICLE	IF	CITATIONS
19	Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. <i>BMC Cancer</i> , 2011, 11, 239.	1.1	51
20	Efficacy, immunogenicity and safety of the HPV16/18 AS04 adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial. <i>International Journal of Cancer</i> , 2014, 135, 2612-2622.	2.3	50
21	Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer. <i>Annals of Internal Medicine</i> , 2018, 168, 20.	2.0	50
22	Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study. <i>Lancet Public Health</i> , The, 2019, 4, e462-e472.	4.7	48
23	Development and validation of an artificial intelligence system for grading colposcopic impressions and guiding biopsies. <i>BMC Medicine</i> , 2020, 18, 406.	2.3	46
24	Management algorithms for cervical cancer screening and precancer treatment for resource-limited settings. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 138, 26-32.	1.0	45
25	A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China. <i>Vaccine</i> , 2021, 39, 35-44.	1.7	42
26	Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China. <i>Cancer Cytopathology</i> , 2011, 119, 387-394.	1.4	41
27	Liquid-based cytology and human papillomavirus testing: A pooled analysis using the data from 13 population-based cervical cancer screening studies from China. <i>Gynecologic Oncology</i> , 2014, 133, 172-179.	0.6	41
28	Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China. <i>Cancer Cytopathology</i> , 2013, 121, 473-482.	1.4	40
29	High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e30.	1.0	36
30	Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china. <i>International Journal of Cancer</i> , 2016, 138, 1453-1461.	2.3	35
31	Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. <i>BMC Health Services Research</i> , 2012, 12, 123.	0.9	34
32	Risk factors for HPV infection and cervical cancer among unscreened women in a high-risk rural area of China. <i>International Journal of Cancer</i> , 2006, 118, 442-448.	2.3	33
33	Acceptability of human papillomavirus vaccine among parents of junior middle school students in Jinan, China. <i>Vaccine</i> , 2015, 33, 2570-2576.	1.7	33
34	A prospective study of age trends of high-risk human papillomavirus infection in rural China. <i>BMC Infectious Diseases</i> , 2014, 14, 96.	1.3	32
35	Efficacy, immunogenicity, and safety of the HPV16/18 AS04 adjuvanted vaccine in Chinese women aged 18–25 years: event-triggered analysis of a randomized controlled trial. <i>Cancer Medicine</i> , 2017, 6, 12-25.	1.3	32
36	Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: Comparison of sensitivity, specificity, and frequency of referral. <i>International Journal of Cancer</i> , 2010, 127, 646-656.	2.3	31

#	ARTICLE	IF	CITATIONS
37	Knowledge of human papillomavirus vaccination and related factors among parents of young adolescents: a nationwide survey in China. <i>Annals of Epidemiology</i> , 2015, 25, 231-235.	0.9	31
38	Human Papillomavirus Vaccine Awareness, Acceptability, and Decision-Making Factors among Chinese College Students. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 3239-3245.	0.5	31
39	Efficacy, immunogenicity and safety of the AS04 HPV16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial. <i>Cancer Medicine</i> , 2019, 8, 6195-6211.	1.3	30
40	Human Papillomavirus Testing for Cervical Cancer Screening: Results From a 6-Year Prospective Study in Rural China. <i>American Journal of Epidemiology</i> , 2009, 170, 708-716.	1.6	29
41	Six-Year Regression and Progression of Cervical Lesions of Different Human Papillomavirus Viral Loads in Varied Histological Diagnoses. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 716-723.	1.2	29
42	Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. <i>International Journal of Cancer</i> , 2014, 135, 2604-2611.	2.3	28
43	Role of active and passive smoking in high-risk human papillomavirus infection and cervical intraepithelial neoplasia grade 2 or worse. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e47.	1.0	28
44	Estimation of cancer cases and deaths attributable to infection in China. <i>Cancer Causes and Control</i> , 2011, 22, 1153-1161.	0.8	26
45	Prevalence of HPV infection and cervical intraepithelial neoplasia and attitudes towards HPV vaccination among Chinese women aged 18-25 in Jiangsu Province. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2011, 23, 25-32.	0.7	26
46	Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in colposcopy and treat approach: A population-based study in rural China. <i>International Journal of Cancer</i> , 2020, 147, 1275-1285.	2.3	26
47	Assessment of quality of life for the patients with cervical cancer at different clinical stages. <i>Chinese Journal of Cancer</i> , 2013, 32, 275-282.	4.9	25
48	The low risk of precancer after a screening result of human papillomavirus negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management. <i>Cancer Cytopathology</i> , 2014, 122, 842-850.	1.4	25
49	Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV positive women. <i>International Journal of Cancer</i> , 2019, 144, 34-42.	2.3	24
50	Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China. <i>Cancer Medicine</i> , 2020, 9, 374-384.	1.3	24
51	Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China. <i>BMC Cancer</i> , 2016, 16, 164.	1.1	23
52	Awareness of and willingness to be vaccinated by human papillomavirus vaccine among junior middle school students in Jinan, China. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 404-411.	1.4	22
53	Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study. <i>Gynecologic Oncology</i> , 2018, 148, 103-110.	0.6	22
54	How university students view human papillomavirus (HPV) vaccination: A cross-sectional study in Jinan, China. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 39-46.	1.4	20

#	ARTICLE	IF	CITATIONS
55	Estimation of Cancer Burden Attributable to Infection in Asia. <i>Journal of Epidemiology</i> , 2015, 25, 626-638.	1.1	18
56	Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China. <i>International Journal of Cancer</i> , 2017, 141, 1110-1119.	2.3	18
57	Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in China. <i>International Journal of Cancer</i> , 2017, 140, 544-554.	2.3	18
58	Risk of high-risk human papillomavirus infection and cervical precancerous lesions with past or current trichomonas infection: a pooled analysis of 25,054 women in rural China. <i>Journal of Clinical Virology</i> , 2018, 99-100, 84-90.	1.6	18
59	Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. <i>BMC Medicine</i> , 2021, 19, 62.	2.3	18
60	Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries. <i>Cancer Letters</i> , 2022, 525, 22-32.	3.2	18
61	Population Effectiveness, Not Efficacy, Should Decide Who Gets Vaccinated Against Human Papillomavirus via Publicly Funded Programs. <i>Journal of Infectious Diseases</i> , 2011, 204, 335-337.	1.9	17
62	Triage options to manage high-risk human papillomavirus positive women: A population-based cross-sectional study from rural China. <i>International Journal of Cancer</i> , 2020, 147, 2053-2064.	2.3	17
63	Risk assessment to guide cervical screening strategies in a large Chinese population. <i>International Journal of Cancer</i> , 2016, 138, 2639-2647.	2.3	16
64	Risk Prediction of Cervical Cancer and Precancers by Type-Specific Human Papillomavirus: Evidence from a Population-Based Cohort Study in China. <i>Cancer Prevention Research</i> , 2017, 10, 745-751.	0.7	16
65	Clinical Evaluation of Human Papillomavirus Detection by careHPV TM Test on Physician-Samples and Self-Samples using The Indicating FTA Elute [®] Card. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 7085-7090.	0.5	16
66	Quality of life in women with cervical precursor lesions and cancer: a prospective, 6-month, hospital-based study in China. <i>Chinese Journal of Cancer</i> , 2014, 33, 339-45.	4.9	15
67	Efficacy of point-of-care thermal ablation among high-risk human papillomavirus positive women in China. <i>International Journal of Cancer</i> , 2021, 148, 1419-1427.	2.3	15
68	Accuracy of triage strategies for human papillomavirus DNA-positive women in low-resource settings: A cross-sectional study in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 496-509.	0.7	15
69	The Natural History of Cervical Cancer in Chinese Women: Results from an 11-Year Follow-Up Study in China Using a Multistate Model. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1298-1305.	1.1	14
70	Optimal Positive Cutoff Points for careHPV Testing of Clinician- and Self-Collected Specimens in Primary Cervical Cancer Screening: an Analysis from Rural China. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1954-1961.	1.8	14
71	The Influence of Human Papillomavirus Genotypes on Visual Screening and Diagnosis of Cervical Precancer and Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 220-223.	0.9	14
72	Analysis of the effectiveness of visual inspection with acetic acid/Lugol's iodine in one-time and annual follow-up screening in rural China. <i>Archives of Gynecology and Obstetrics</i> , 2012, 285, 1627-1632.	0.8	13

#	ARTICLE	IF	CITATIONS
73	The concordance of HPV DNA detection by Hybrid Capture 2 and careHPV on clinician- and self-collected specimens. <i>Journal of Clinical Virology</i> , 2014, 61, 553-557.	1.6	13
74	Risk stratification of HPV 16 DNA methylation combined with E6 oncoprotein in cervical cancer screening: a 10-year prospective cohort study. <i>Clinical Epigenetics</i> , 2020, 12, 62.	1.8	12
75	Distribution of high-risk human papillomavirus genotype prevalence and attribution to cervical precancerous lesions in rural North China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 663-672.	0.7	12
76	Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening. <i>BMC Cancer</i> , 2015, 15, 848.	1.1	11
77	Elevated Expression of Human Papillomavirus-16/18 E6 Oncoprotein Associates with Persistence of Viral Infection: A 3-Year Prospective Study in China. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1167-1174.	1.1	11
78	Estimating long-term clinical effectiveness and cost-effectiveness of HPV 16/18 vaccine in China. <i>BMC Cancer</i> , 2016, 16, 848.	1.1	11
79	Durability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China. <i>Gynecologic Oncology</i> , 2018, 151, 221-228.	0.6	11
80	Role of Epstein-Barr Virus and Human Papillomavirus Coinfection in Cervical Intraepithelial Neoplasia in Chinese Women Living With HIV. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 703259.	1.8	11
81	Role of Human Papillomavirus DNA Load in Predicting the Long-term Risk of Cervical Cancer: A 15-Year Prospective Cohort Study in China. <i>Journal of Infectious Diseases</i> , 2019, 219, 215-222.	1.9	10
82	Combined Screening of Cervical Cancer, Breast Cancer and Reproductive Tract Infections in Rural China. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 3529-3533.	0.5	10
83	Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer. <i>Preventive Medicine</i> , 2022, 155, 106906.	1.6	10
84	Age-Specific Prevalence of Anal and Cervical Human Papillomavirus Infection and High-Grade Lesions in 11 177 Women by Human Immunodeficiency Virus Status: A Collaborative Pooled Analysis of 26 Studies. <i>Journal of Infectious Diseases</i> , 2023, 227, 488-497.	1.9	10
85	The association between dietary intake and cervical intraepithelial neoplasia grade 2 or higher among women in a high-risk rural area of china. <i>Archives of Gynecology and Obstetrics</i> , 2011, 284, 973-980.	0.8	9
86	Random biopsy in colposcopy-negative quadrant is not effective in women with positive colposcopy in practice. <i>Cancer Epidemiology</i> , 2015, 39, 237-241.	0.8	9
87	Pooled analysis on the necessity of random 4-quadrant cervical biopsies and endocervical curettage in women with positive screening but negative colposcopy. <i>Medicine (United States)</i> , 2017, 96, e6689.	0.4	9
88	Outcomes in women with biopsy-confirmed cervical intraepithelial neoplasia grade 1 or normal cervix and related cofactors: A 15-year population-based cohort study from China. <i>Gynecologic Oncology</i> , 2020, 156, 616-623.	0.6	9
89	A nationwide post-marketing survey of knowledge, attitudes and recommendations towards human papillomavirus vaccines among healthcare providers in China. <i>Preventive Medicine</i> , 2021, 146, 106484.	1.6	9
90	Temporal Trends and Projection of Cancer Attributable to Human Papillomavirus Infection in China, 2007-2030. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1130-1136.	1.1	9

#	ARTICLE	IF	CITATIONS
91	Triage performance and predictive value of the human gene methylation panel among women positive on self-collected HPV test: Results from a prospective cohort study. <i>International Journal of Cancer</i> , 2022, 151, 878-887.	2.3	9
92	Comparison of the performance of paired urine and cervical samples for cervical cancer screening in screening population. <i>Journal of Medical Virology</i> , 2020, 92, 234-240.	2.5	8
93	Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial. <i>BMC Infectious Diseases</i> , 2020, 20, 846.	1.3	8
94	A retrospective analysis of the utility of endocervical curettage in screening population. <i>Oncotarget</i> , 2017, 8, 50141-50147.	0.8	8
95	Economic evaluation of cervical cancer screening strategies in urban China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 974-983.	0.7	8
96	Quantitative evaluation of radon, tobacco use and lung cancer association in an occupational cohort with 27 follow-up years. <i>Ecotoxicology and Environmental Safety</i> , 2022, 232, 113233.	2.9	8
97	Elimination of Cervical Cancer: Challenges Promoting the HPV Vaccine in China. <i>Indian Journal of Gynecologic Oncology</i> , 2021, 19, 51.	0.1	7
98	Arsenic, tobacco use, and lung cancer: An occupational cohort with 27 follow-up years. <i>Environmental Research</i> , 2022, 206, 112611.	3.7	7
99	Systematic Review and Meta-Analysis of Individual Patient Data to Assess the Sensitivity of Cervical Cytology for Diagnosis of Cervical Cancer in Low- and Middle-Income Countries. <i>Journal of Global Oncology</i> , 2017, 3, 524-538.	0.5	5
100	Impact of International Collaborative Training Programs on Medical Students' Research Ability. <i>Journal of Cancer Education</i> , 2018, 33, 511-516.	0.6	5
101	Association Between Common Vaginal Infections and Cervical Non-Human Papillomavirus (HPV) 16/18 Infection in HPV-Vaccinated Women. <i>Journal of Infectious Diseases</i> , 2021, 223, 445-451.	1.9	5
102	Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 955-964.	1.4	5
103	Health economic evaluation of primary human papillomavirus screening in urban populations in China. <i>Cancer Epidemiology</i> , 2021, 70, 101861.	0.8	5
104	Performance of cervical cancer screening and triage strategies among women living with HIV in China. <i>Cancer Medicine</i> , 2021, 10, 6078-6088.	1.3	5
105	Naturally acquired HPV antibodies against subsequent homotypic infection: A large-scale prospective cohort study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 13, 100196.	1.3	5
106	Effect of Time Since Smoking Cessation on Lung Cancer Incidence: An Occupational Cohort With 27 Follow-Up Years. <i>Frontiers in Oncology</i> , 2022, 12, 817045.	1.3	5
107	Distribution of cervical intraepithelial neoplasia on the cervix in Chinese women: pooled analysis of 19 population based screening studies. <i>BMC Cancer</i> , 2015, 15, 485.	1.1	4
108	Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 383-394.	0.7	4

#	ARTICLE	IF	CITATIONS
109	Epidemiologic and Health Economic Evaluation of Cervical Cancer Screening in Rural China. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 1317-1325.	0.5	4
110	Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or. <i>Clinical Laboratory</i> , 2018, 64, 1363-1371.	0.2	4
111	p16 Immunohistochemistry Interpretation by Nonpathologists as an Accurate Method for Diagnosing Cervical Precancer and Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 207-211.	0.9	3
112	Inequalities in Cervical Cancer Screening Uptake Between Chinese Migrant Women and Local Women: A Cross-Sectional Study. <i>Cancer Control</i> , 2021, 28, 107327482098579.	0.7	3
113	Prevalence and risk factors for anogenital HPV infection and neoplasia among women living with HIV in China. <i>Sexually Transmitted Infections</i> , 2021, , sextrans-2021-055019.	0.8	3
114	Prospective comparison of hybrid capture 2 and SPF10-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e66.	1.0	2
115	Comment on "Will HPV vaccination prevent cervical cancer". <i>BMC Medicine</i> , 2020, 18, 115.	2.3	2
116	Clinical evaluation of p16 ^{INK4a} immunocytology in cervical cancer screening: A population-based cross-sectional study from rural China. <i>Cancer Cytopathology</i> , 2021, 129, 679-692.	1.4	2
117	Low cost versus other screening tests to detect cervical cancer or precancer in developing countries. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	1
118	Training Future Leaders: Experience from China-ASEAN Cancer Control Training Program. <i>Journal of Cancer Education</i> , 2019, 34, 1067-1073.	0.6	1
119	Effect of Sequential Rounds of Cervical Cancer Screening on Management of HPV-positive Women: A 15-year Population-based Cohort Study from China. <i>Cancer Prevention Research</i> , 2021, 14, 363-372.	0.7	1
120	Comprehensive cervical cancer prevention and control in the Asia Pacific region: the 6th Biennial Conference of the Asia Oceania Research Organization on Genital Infections & Neoplasia (AOGIN). <i>Journal of Gynecologic Oncology</i> , 2014, 25, 170.	1.0	0
121	Reply to Letter: Using novel risk stratification statistics to better understand the value of screening tests. <i>International Journal of Cancer</i> , 2016, 139, 1669-1669.	2.3	0
122	Has the human papillomavirus (HPV) immunization programme improved obstetric outcomes in spontaneous delivery? An ecological study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 262, 221-227.	0.5	0